Turkey Tail Mushroom Extract
Trametes versicolor
Also known as: Coriolus versicolor, PSK, PSP, Yun Zhi
This ingredient is classified as unclassified risk (GIRI score: 2.0/10).
Safety Profile
Information not yet available for this ingredient profile.
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Turkey Tail is a medicinal mushroom used for immune modulation and studied as an adjunct in oncology. It is generally well tolerated. GI side effects and darkening of finger nails have been reported. May interact with immunosuppressant drugs. Avoid in individuals with mushroom allergies or transplant patients on immunosuppressants.
Biological and Chemical Classification
- Scientific Name
- Trametes versicolor
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Immune Support
- Evidence consistency: High consistency across studies (100%)
- No significant safety signals identified in the reviewed literature.
The available scientific evidence for Turkey Tail Mushroom Extract indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 26 მარ 2026, 14:01
Evidence Distribution
-
Observational / other LOW evidence YELLOWMagic Mushrooms? White-Rot Fungal Degradation of Psychoactive Pharmaceuticals in Biosolids. ↗Burgener K et al.. Magic Mushrooms? White-Rot Fungal Degradation of Psychoactive Pharmaceuticals in Biosolids.. ACS Environ Au. 2026. PMID:41867299.PMID 41867299 ↗Journal ACS Environ AuYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41867299/
-
Observational / other LOW evidence YELLOWFungal removal of OPFRs from urban wastewater in a rotary drum bioreactor. ↗Losantos D et al.. Fungal removal of OPFRs from urban wastewater in a rotary drum bioreactor.. J Hazard Mater. 2026. PMID:41846127.PMID 41846127 ↗Journal J Hazard MaterYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41846127/
-
Observational / other LOW evidence YELLOWThe Potential of Size-Exclusion Chromatography for Evaluating the Suitability of Hydrophilic Extracts in Wood Preservation. ↗Oberle A et al.. The Potential of Size-Exclusion Chromatography for Evaluating the Suitability of Hydrophilic Extracts in Wood Preservation.. Polymers (Basel). 2026. PMID:41829273.PMID 41829273 ↗Journal Polymers (Basel)Year 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41829273/
-
Observational / other LOW evidence YELLOWTrametes versicolor mycelium fermenting whole kidney beans into tempeh-like product. ↗Li X et al.. Trametes versicolor mycelium fermenting whole kidney beans into tempeh-like product.. Int J Food Microbiol. 2026. PMID:41806721.PMID 41806721 ↗Journal Int J Food MicrobiolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41806721/
-
Observational / other LOW evidence YELLOWClinical evidence on a Coriolus versicolor-based vaginal gel for HPV-related cervical disease: a narrative review. ↗Su00e1nchez Du00edaz E et al.. Clinical evidence on a Coriolus versicolor-based vaginal gel for HPV-related cervical disease: a narrative review.. Chin Clin Oncol. 2026. PMID:41797457.PMID 41797457 ↗Journal Chin Clin OncolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41797457/
-
Observational / other LOW evidence YELLOWNutritional, Anti-inflammatory, and in-silico inhibitory Studies of Trametes versicolor (L.) Lloyd and Flammulina velutipes (Curtis) on HER2 breast cancer protein. ↗Iyekekpolor OM et al.. Nutritional, Anti-inflammatory, and in-silico inhibitory Studies of Trametes versicolor (L.) Lloyd and Flammulina velutipes (Curtis) on HER2 breast cancer protein.. Biochem Biophys Rep. 2026. PMID:41769067.PMID 41769067 ↗Journal Biochem Biophys RepYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41769067/
-
Observational / other LOW evidence YELLOWImmobilization of Trametes versicolor Laccase Enzyme to Cu-silica Aerogel and its Decolorization of Synthetic Dyes. ↗Isik S et al.. Immobilization of Trametes versicolor Laccase Enzyme to Cu-silica Aerogel and its Decolorization of Synthetic Dyes.. Appl Biochem Biotechnol. 2026. PMID:41762358.PMID 41762358 ↗Journal Appl Biochem BiotechnolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41762358/
-
Observational / other LOW evidence YELLOWLaccase Immobilization on Carbon-Based Materials Derived from Spent Brewery Grains: Optimization and Stability Evaluation. ↗Almeida u00c2 et al.. Laccase Immobilization on Carbon-Based Materials Derived from Spent Brewery Grains: Optimization and Stability Evaluation.. Molecules. 2026. PMID:41752515.PMID 41752515 ↗Journal MoleculesYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41752515/
-
Observational / other LOW evidence YELLOWFungal enzyme-driven precipitation polymerization: Trapping estrogenic chemicals to block vegetable contamination. ↗Yin Q et al.. Fungal enzyme-driven precipitation polymerization: Trapping estrogenic chemicals to block vegetable contamination.. J Hazard Mater. 2026. PMID:41720027.PMID 41720027 ↗Journal J Hazard MaterYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41720027/
-
Observational / other LOW evidence YELLOWFungal extracts influence lifespan and immune responses in the Carniolan honey bee (Apis mellifera carnica, Pollmann 1879). ↗Ansaloni LS et al.. Fungal extracts influence lifespan and immune responses in the Carniolan honey bee (Apis mellifera carnica, Pollmann 1879).. Sci Rep. 2026. PMID:41714705.PMID 41714705 ↗Journal Sci RepYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41714705/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Turkey Tail Mushroom Extract. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for Turkey Tail Mushroom Extract
A score of 2.0 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.